Robotic total gastrectomy for carcinoma in the remnant stomach: a comparison with laparoscopic total gastrectomy

Gastroenterol Rep (Oxf). 2021 Jul 19;9(6):583-588. doi: 10.1093/gastro/goab021. eCollection 2021 Dec.

Abstract

Background: Total gastrectomy for carcinoma in the remnant stomach (CRS) remains a technically demanding procedure. Whether robotic surgery is superior, equal, or inferior to laparoscopic surgery in patients with CRS is unclear. This study was designed to compare the efficacy and safety of robotic total gastrectomy (RTG) and laparoscopic total gastrectomy (LTG) for the treatment of CRS.

Methods: In this cohort study, we retrospectively analysed the data from patients who underwent RTG or LTG for CRS at Southwest Hospital (Chongqing, China) between May 2006 and October 2019. The surgical outcomes, post-operative complications, and survival outcomes between the two groups were compared.

Results: Compared with LTG, RTG was associated with similar effective operation time (272.0 vs 297.9 min, P = 0.170), higher total costs (105,967.2 vs 81,629.5 RMB, P < 0.001), and less estimated blood loss (229.2 vs 288.8 mL, P = 0.031). No significant differences were found between the robotic and laparoscopic groups in terms of conversion rate, time to first flatus, time to first soft diet, post-operative hospital stay, post-operative complications, R0 resection rate, and number of retrieved lymph nodes (all P > 0.05). The 3-year disease-free survival and 3-year overall survival rates were comparable between the two groups (65.5% vs 57.5%, P = 0.918; 69.0% vs 60.0%, P = 0.850, respectively).

Conclusions: RTG is a safe and feasible procedure for the treatment of CRS and could serve as an optimal treatment for CRS.

Keywords: carcinoma in the remnant stomach; laparoscopic gastrectomy; robotic gastrectomy; total gastrectomy.